Eumycetoma is a chronic progressive disabling and destructive inflammatory disease which is commonly caused by the fungus Madurella mycetomatis. It is characterized by the formation of multiple discharging sinuses. It is usually treated by antifungal agents but it is assumed that the therapeutic efficiency of these agents is reduced by the co-existence of Staphylococcus aureus co-infection developing in these sinuses. This prospective study was conducted to investigate the safety, efficacy and clinical outcome of combined antibiotic and antifungal therapy in eumycetoma patients with superimposed Staphylococcus aureus infection. The study enrolled 337 patients with confirmed M. mycetomatis eumycetoma and S. aureus co-infection. Patients were allocated into three groups; 142 patients received amoxicillin-clavulanic acid and ketoconazole, 93 patients received ciprofloxacin and ketoconazole and 102 patients received ketoconazole only. The study showed that, patients who received amoxicillin-clavulanic acid and ketoconazole treatment had an overall better clinical outcome compared to those who had combined ciprofloxacin and ketoconazole or to those who received ketoconazole only. In this study, 60.6% of the combined amoxicillin-clavulanic acid/ketoconazole group showed complete or partial clinical response to treatment compared to 30.1% in the ciprofloxacin/ketoconazole group and 36.3% in the ketoconazole only group. The study also showed that 64.5% of the patients in the ciprofloxacin/ketoconazole group and 59.8% in the ketoconazole only group had progressive disease and poor outcome. This study showed that the combination of amoxicillin-clavulanic acid and ketoconazole treatment is safe and offers good clinical outcome and it is therefore recommended to treat eumycetoma patients with Staphylococcus aureus co-infection.
Mycetoma, a unique neglected tropical disease, is characterised by massive deformity and disability presenting with painless subcutaneous mass, multiple sinuses that produce sero-purulent discharge. Secondary bacterial infection is common in mycetoma and it is assumed that, this bacterial co-infection reduces the effectiveness of the antifungal treatment and is responsible for the poor treatment outcome. To investigate this hypothesis, this study examined the combination of Ketoconazole and antibiotics in two groups of patients with eumycetoma and Staphylococcus aureus (S. aureus) co-infection. The first group received ketoconazole and amoxicillin-clavulanic and the second group received ciprofloxacin and ketoconazole. The study also included a historical group of patients who had only ketoconazole as a control group. Patients who had amoxicillin-clavulanic acid and ketoconazole had an overall better clinical outcome and superior infection eradication compared to the two other groups. It can be concluded that the combination of amoxicillin-clavulanic acid and ketoconazole is safe treatment and offers better clinical outcome in eumycetoma patients with S. aureus co-infection.
Citation: Mhmoud NA, Fahal AH, Mahgoub ES, van de Sande WWJ (2014) The Combination of Amoxicillin-Clavulanic Acid and Ketoconazole in the Treatment of Madurella mycetomatis Eumycetoma and Staphylococcus aureus Co-infection. PLoS Negl Trop Dis 8(6): e2959. https://doi.org/10.1371/journal.pntd.0002959
Editor: Pamela L. C. Small, University of Tennessee, United States of America
Received: December 14, 2013; Accepted: May 7, 2014; Published: June 19, 2014
Copyright: © 2014 Mhmoud et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors received no specific funding for this study.
Competing interests: The authors have declared that no competing interests exist.
Mycetoma is a chronic granulomatous subcutaneous infection which is endemic in the tropical and subtropical regions of Central and South-America, Asia and Africa. It is caused by either bacteria (actinomycetoma) or fungi (eumycetoma). Eumycetoma is highly endemic in Sudan and commonly caused by the fungus Madurella mycetomatis , , , . Clinically, mycetoma presents as a slowly progressive painless subcutaneous swelling commonly at the site of previous trauma. Multiple secondary nodules evolve within the swelling, suppurate and drain serous, sero-sanguinous or purulent discharge –. The discharge is initially sterile, but later on, may become exposed to secondary bacterial infections due to poor hygiene . Routine monitoring follow-up visits of these patients at the Mycetoma Research Centre (MRC) of the University of Khartoum, Sudan documented recurrent bacterial co-infections with S. aureus infection , .
Eumycetoma continues to pose management challenges. The current management approach consists of a prolonged course of drugs combined with surgery. Unfortunately, the cure rate is rather low with a high recurrence rate -. Therefore there is a desperate need to make available novel antifungal agents and to develop new approaches in the endemic areas.
Several studies have confirmed that, the majority of the S. aureus infection is of endogenous origin and nasal carriage of S. aureus is the risk factor for developing a co-infection in many skin and soft tissue infections –. In general, local bacterial co-infections may disturb the local tissue environment reducing the antifungal drug efficacy, producing local metabolites which are likely to induce changes that affect the healing process and increase drug resistance , . Therefore controlling bacterial co-infection by the use of appropriate antibiotics could normalize the tissue environment and therefore augment the efficacy of antifungal agents in the management of eumycetoma.
With this background, this prospective study was set out to determine the safety and efficacy of the combination of ketoconazole and amoxicillin-clavulanic acid or ciprofloxacin as a first line treatment for patients with eumycetoma caused by M. mycetomatis and S. aureus co-infection.
Materials and Methods
This prospective study was conducted at the Mycetoma Research Centre, University of Khartoum in the period between January 2011 and June 2013. It included 337 consecutive patients with confirmed Madurella mycetomatis eumycetoma; based on a confirmed grains culture, fine needle aspiration for cytology and/or histopathologic examination of surgical biopsies. All patients had a S. aureus co-infection at the time of enrollment. None of the patients had previous surgical or medical treatment for eumycetoma.
All patients were carefully interviewed. Demographic information was gathered on gender, age, social habits, co-morbidities and history of hospitalization in the past year. All patients underwent a thorough general and local physical examination. This included lesion size in cm from fixed points, the number of active sinuses, skin attachment to deep structures and disability.
The study population was divided according to their lesions' size into three groups; massive lesion (>10 cm in diameter), moderate lesion (5–10 cm in diameter) and small lesion (<5 cm in diameter).
All patients had full blood count examination, hepatic and renal function tests, radiological examination of the affected site (anterio-posterior and lateral views) and lesion ultrasound examination. Anterior nares and sinuses swab cultures for S. aureus were obtained from all patients as previously described , . The bacteria were cultured and identified to the species level by Gram's staining, colonial morphology, biochemical testing; catalase, DNAse and Coagulase tests. A co-infection was defined as a deep wound infection as documented clinically by treating clinician and culture isolates.
According to the results obtained from the sinus swab culture, antibiotics were given in prolonged courses, each course lasted 12 weeks. Several courses were administered. In this study, the two common antibiotics that showed organism's sensitivity were amoxicillin-clavulanic acid and ciprofloxacin. Patients were allocated according to their bacteriology culture results into two groups; the amoxicillin-clavulanic acid and ketoconazole group and the ciprofloxacin and ketoconazole group. Ketoconazole was the eumycetoma drug of choice at the MRC during the study duration.
One hundred forty two patients received one gram amoxicillin-clavulanic acid orally twice daily combined with oral ketoconazole 400 mg twice daily and 93 patients received oral ciprofloxacin 500 mg twice daily combined with oral ketoconazole 400 mg twice daily. Another 102 patients from the MRC records who only received 400 mg ketoconazole orally twice daily were selected and included as a control group.
All patients were followed up closely every four weeks for clinical, hepatic and renal functions assessment. The medical treatment duration ranged between 6 months and one year depending on clinical response followed by wide surgical excision.
Cure and amputation were considered as study outcomes. Cure was defined as complete mass disappearance, healed sinuses, normal skin and absence of hyper-reflective echoes and cavities on ultra-sound examination .
Ethical clearance was obtained from Soba University Hospital Ethical Committee. Patients gave written informed consent.
One way ANOVA was used to compare the mean of age, duration and occupation for the three study groups. The clinical response to the combinations of ketoconazole and the antibiotics was assessed with the Fisher exact test. The significance of differences in patients and control were calculated and p-value of <0.05 considered statistically significant. All statistical analyses were performed using SPSS for Windows v11.0 statistical analysis software.
To test the hypothesis that eradicating secondary bacterial infections would have a positive effect on the outcome of eumycetoma treatment, 337 patients with confirmed M. mycetomatis and S. aureus co-infection were enrolled in this study (Table 1).
All S. aureus strains were assessed for their susceptibility to a large panel of antimicrobial agents. All strains were susceptible to amoxicillin-Clavulanic acid and/or ciprofloxacin.
Adding Amoxicillin-Clavulanic Acid but Not Ciprofloxacin to Ketoconazole Treatment Improves the Therapeutic Outcome of Ketoconazole Treated Mycetoma Patients with S. aureus Co-infection
The treatment duration in the amoxicillin-clavulanic acid group ranged between 3 and 12 months (mean 9.6 months) and the bacterial co-infection was eradicated in 97.2% of the patients. In the ciprofloxacin group, the treatment duration ranged between 3 and 12 months (mean 10 months) and in this group, none of the bacterial co-infection was eradicated.
Patients who had received a combination of amoxicillin-clavulanic acid and ketoconazole had an overall better clinical outcome than those received a combination of ciprofloxacin and ketoconazole or ketoconazole alone.
In the amoxicillin-clavulanic acid group, 39 patients (27.5%), showed complete and 47 patients (33.1%) had partial clinical response to treatment compared to 13 patients (14%) complete and 15 patients (16.1%) had partial response in the ciprofloxacin group. In the ketoconazole group 22 patients (21%) had complete response and 15 patients (14.7%) had partial response. Table 2,3.
The study also showed that 60 patients (64.5%) of the ciprofloxacin group and 61 patients (59.8%) of the ketoconazole monotherapy group had progressive disease and poor outcome, (Table 3).
Based on these results, it can be concluded that, the combination of amoxicillin-Clavulanic acid and ketoconazole has superior outcome in the treatment of eumycetoma patients with S. aureus co-infection. This also suggests that treating co-infection influences the outcome of the eumycetoma treatment with ketoconazole.
Adding Amoxicillin-Clavulanic Acid but Not Ciprofloxacin to Ketoconazole Treatment Improves the Skin Abnormalities, Pain and Mobility of Eumycetoma Patients with S. aureus Co-infection
In addition, to influencing the outcome of the ketoconazole therapy, we investigated if treating the co-infection also play a role in improving the skin abnormalities, the pain and even the disability observed in the eumycetoma patients.
At the end of the study, 34.5% of the amoxicillin-clavulanic acid patients group had skin appearance improvement in contra-distinction to patients of the other two groups. (Fisher exact, p = 0.000).
Although mycetoma is generally regarded as painless, pain can be induced by secondary bacterial infections. In the amoxicillin-clavulanic acid treated group significantly fewer patients (18 patients; 12.7%) suffered from pain in the lesion compared to the ciprofloxacin treated group (79 patients; 85%), (Fisher exact, p = 0.000).
At the end of the treatment period, the overall mobility of the patients who received amoxicillin-clavulanic acid was significantly better than those receiving ciprofloxacin. In the amoxicillin-clavulanic acid group 123 out of 139 patients, had no disability, versus 2 of the 93 in the ciprofloxacin treated group (Fisher exact, p = 0.000). The degree of disability was more severe in the ciprofloxacin treated group than in the amoxicillin-clavulanic acid treated group. Of the 91 patients with disabilities in the ciprofloxacin-treated group, 77 had severe disability, while only four out of the 16 in the amoxicillin-clavulanic acid treated group were severely disabled (Fisher exact, p = 0.00). Four patients in amoxicillin-clavulanic acid group and 11 patients in ciprofloxacin group had amputation.
Combination of Amoxicillin-Clavulanic Acid or Ciprofloxacin and Ketoconazole for the Treatment of Eumycetoma Patients with S. aureus Co-infection Does Not Affect the Hepatic Function
Ketoconazole administration in high doses is hepatotoxic and therefore patients require close monitoring of their hepatic functions during treatment . Adding other medication to the ketoconazole treatment regime could further influence the hepatic functions. The total protein, albumin, globulin, bilirubin and the liver enzymes; alkaline phosphates, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate-pyruvate transaminase (SGPT) were measured at the start of the study, after one month, 3 months, 6 months and 12 months in this study. The addition of amoxicillin-clavulanic acid or ciprofloxacin to ketoconazole did not result in hepatic toxicity. This suggests the safety of this combination.
Previous studies and clinical observations documented that, bacterial co-infection is common in eumycetoma patients and S. aureus is the most commonly isolated bacterial species . The bacterial infection may disturb the local environment, reduce drug efficacy, and could produce local metabolites that may induce changes affecting the healing process and increase drug resistance , . Hence, it can be hypothesized that secondary bacterial infections can influence the therapeutic outcome of the antifungal treatment for eumycetoma patients.
In this study, S. aureus strains were tested for their susceptibility to a large group of antibiotics and amoxicillin-clavulanic acid and ciprofloxacin appeared to be the most effective ones. It is interesting to note that, amoxicillin-clavulanic acid eradicated the infection in most of the patients whereas the bacterial co-infection persisted in all patients in the ciprofloxacin group. The explanation of this is unclear but cases of ciprofloxacin resistant staphylococci were reported even during the drug investigational stage, and since its introduction into routine clinical use, there has been increasing reports of ciprofloxacin-resistant staphylococci –. It appears that once resistance developed, person-to-person transmission within an environment favorable to spread resulted in widespread dissemination of resistant strains , .
Amoxicillin-clavulanic acid treatment resulted in eradication of S. aureus co-infection in the affected patients, it is therefore not surprisingly, that clinical improvement in these patients manifested by reduction of lesion size, number of active sinuses and less disability compared to the ciprofloxacin and the ketoconazole monotherapy groups.
In untreated mycetoma, particularly those with lesions containing multiple active sinuses, disease progression results in further tissue damage and destruction. It is highly likely that the bacterial co-infection has a major role to play in the disease progression .
It can be extrapolated from this observation that, the improved clinical outcome is due to co-infection eradication leading to less disease progression in the amoxicillin-clavulanic acid group compared to the other groups.
In mycetoma, the criteria of clinical improvement include lesion's size reduction, reduced active sinuses, normal skin and reduced disability. All these were documented in amoxicillin-clavulanic acid group which is possibly due to eradiation of the co-infection. It is interesting to note that the clinical improvement was observed within the first three months of amoxicillin-clavulanic acid treatment. This was not observed in the ciprofloxacin group and it is likely to be due to the persistence of the secondary bacterial infection and its local effects on the lesions.
The results obtained in this study are encouraging as eradication of the co-infection was associated with better clinical outcome. However ketoconazole the gold standard treatment for mycetoma has a narrow safety margins. Van de Sande and associates , Van Belkum and colleagues , Kloezen and associates  showed in in vitro susceptibility testing, encouraging results with the new generation of the azole group. –. Further studies combining amoxicillin-clavulanic acid with voriconazole or posaconazole are recommended. Both voriconazole and posaconazole have a better safety-profile than the currently used ketoconazole - and therefore avoiding liver toxicity and hepatitis .
In conclusion, amoxicillin-clavulanic acid proved to be highly effective in eradication of S. aureus co-infection in patients with eumycetoma due to M. mycetomatis and was associated with good clinical outcome and safety profile with no reported hepatic toxicity. Combination of amoxicillin-clavulanic acid and new less toxic azole drugs is recommended to avoid the toxic effect of ketoconazole which was recently banned by the Food and Drugs Administration (USA) (http://www.fda.gov/drugs/drugsafety/ucm362415.htm).
Conceived and designed the experiments: NAM AHF ESM WWJvdS. Performed the experiments: NAM AHF ESM WWJvdS. Analyzed the data: NAM AHF ESM WWJvdS. Contributed reagents/materials/analysis tools: NAM AHF ESM WWJvdS. Wrote the paper: NAM AHF ESM WWJvdS.
- 1. Fahal AH, Hassan MA (1992) Mycetoma. Br J Surg 79(11): 1138–1141.
- 2. Fahal AH (2004) Mycetoma thorn on the flesh. Review article. Trans R Soc Trop Med Hyg 98(1): 3–11.
- 3. Fahal AH (2011) Mycetoma. Review article, Khartoum Med J 4(1): 514–523.
- 4. Ahmed AA, van de Sande WW, Fahal A, Bakker-Woudenberg I, Verbrugh H, et al. (2007) Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis 20(2): 146–51.
- 5. Ahmed AOA, Fahal AH, Abugroun EAM, Zijlstra E, Belkum A van, et al. (1998) Unexpected high prevelance of secondary bacterial infection in mycetoma. J Clin Microbiol 36(3): 850–851.
- 6. Zein HAM, Fahal AH, Mahgoub ES, EL Hassan T, Abdel Rahman (2012) ME (2012) The Predictors of Cure, Amputation & Follow-up dropout among Mycetoma Patients as seen at The Mycetoma Research Centre, University of Khartoum. Trans R Soc Trop Med Hyg 106(11): 639–44.
- 7. Fahal AH, Rahman IA, El-Hassan AM, Rahman ME, Zijlstra EE (2011) The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 105: 127–32.
- 8. Mahgoub ES, Gumaa SA (1984) Ketoconazole in the treatment of eumycetoma due to madurella mycetomi. Trans Roy Soc Trop Med Hyg 78: 376–379.
- 9. Nakashima AK, Allen JR, Martone WJ, Plikaytis BD, Stover B, et al. (1984) Epidemic bullous impetigo in a nursery due to a nasal carrier of Staphylococcus aureus: role of epidemiology and control measures. Infect Control. 5: 326–31.
- 10. Vandenbergh MF, Verbrugh HA (1999) Carriage of Staphylococcus aureus: epidemiology and clinical relevance. J Lab Clin Med 133: 525–34.
- 11. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, et al. (2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 5(12): 751–62.
- 12. Kluytmans J, van Belkum A, Verbrugh H (1997) Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 10: 505–20.
- 13. Strommenger C, Braulke D, Heuck C, Schmidt B, Pasemann U, et al. (2008) spa Typing of Staphylococcus aureus as a Frontline Tool in Epidemiological Typing. J Clin Microbiol 46(2): 574–81.
- 14. Struelens MJ, Hawkey PM, French GL, Witte W, Tacconelli E (2009) Laboratory tools and strategies for methicillin-resistant Staphylococcus aureus screening, surveillance and typing: state of the art and unmet needs. Clin Microbiol Infect 15(2): 112–119.
- 15. Baggett HC, Hennessy TW, Rudolph K, Bruden D, Reasonover A, et al. (2004) Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis. 189: 1565–73.
- 16. Wang JT, Chang SC, Ko WJ, Chang YY, Chen ML, et al. (2001) A hospital-acquired outbreak of methicillin-resistant Staphylococcus aureus infection initiated by a surgeon carrier. J Hosp Infect. 47: 104–9.
- 17. Solberg CO (2000) Spread of Staphylococcus aureus in hospitals: causes and prevention. Scand J Infect Dis. 32: 587–95.
- 18. Baggett HC, Hennessy TW, Rudolph K, Bruden D, Reasonover A, et al. (2004) Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis. 189: 1565–73.
- 19. Huang HN, Pan CY, Chan YL, Chen JY, Wu CJ (2014) Use of the antimicrobial peptide pardaxin (GE33) to protect against methicillin-resistant Staphylococcus aureus infection in mice with skin injuries. Antimicrob Agents Chemother. 58(3): 1538–45
- 20. Yeboah-Manu D, Kpeli GS, Ruf MT, Asan-Ampah K, Quenin-Fosu K, Owusu-Mireku et al (2013) Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis. 2 7(5): e2191
- 21. Fahal AH (2007). Evidence-based guidelines for the management of mycetoma patients. Mycetoma Research Centre, Sudan. http://www.mycetoma.edu.sd/academic/updates_MMG.htm
- 22. Daum TE, Schaberg DR, Terpenning MS, Sottile WS, Kauffman CA (1990) Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother 34 (9): 1862–3.
- 23. Humphreys H, Mulvihill E (1985) Ciprofloxacin-resistant Staphylococcus aureus. Lancet. 17 2(8451): 383.
- 24. Isaacsa RD, Kunkea PJ, Cohena RL, Smitha JW, LornaM Milneb, et al. (1988) Ciprofloxacin resistance in epidemic methicillin-resistant staphylococcus aureus 332. (8615): 843.
- 25. Kotilainen P, Nikoskelainen J, Huovinen P (1990) Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis. 161(1): 41–4.
- 26. Maple P, Hamilton-Miller J, Brumfitt W (1989) Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 8(7): 622–4.
- 27. Mulligan ME, Ruane PJ, Johnston L, Wong P, Wheelock JP, et al. (1987) Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med. 27 82(4A): 215–9.
- 28. Fahal AH (2010). Mycetoma. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. 3rd ed. Philadelphia: Saunders Elsevier 234–9 p.
- 29. Van de Sande WW, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, van Belkum A (2005) Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob.. Agents Chemother 49: 1364–1368.
- 30. Van Belkum A, Fahal AH, van de Sande WWJ (2011) In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother 55: 1771–1773.
- 31. Kloezen W, Meis JF, Curfs-Breuker I, Fahal AH, van de Sande WWJ (2012) In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrob Agents Chemother 56: 6054–6056.
- 32. Lacroix C, de Kerviler E, Morel P, Derouin F, Feuilhade de Chavin M (2005) Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermato 152 (5): 1067–8.
- 33. Negroni R, Tobón A, Bustamante B, Shikanai-Yasuda MA, Patino H, et al. (2005) Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 47(6): 339–46.
- 34. Porte L, Khatibi S, Hajj LE, Cassaing S, Berry A, et al. (2006) Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 100(9): 891–4.
- 35. Loulergue P, Hot A, Dannaoui E, Dallot A, Poirée S, et al. (2006) Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg. 75(6): 1106–7.
- 36. García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH (1999) A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48(6): 847–52.